

# Cloning and expression of human TRAAK, a polyunsaturated fatty acids-activated and mechano-sensitive K<sup>+</sup> channel

Florian Lesage, François Maingret, Michel Lazdunski\*

*Institut de Pharmacologie Moléculaire et Cellulaire, CNRS-UPR 411, 660, route des Lucioles, Sophia Antipolis, 06560 Valbonne, France*

Received 12 February 2000; received in revised form 11 March 2000

Edited by Pierre Jolles

**Abstract** The two P domain hTRAAK K<sup>+</sup> channel has been cloned from human brain. hTRAAK cDNA encodes a 393 amino acid polypeptide with 88% of homology with its mouse counterpart. The hTRAAK gene has been mapped to chromosome 11q13 and the study of its organization indicates that the hTRAAK open reading frame is contained in six exons. hTRAAK is expressed abundantly in brain and placenta. In COS cells, hTRAAK currents are K<sup>+</sup>-selective, instantaneous and non-inactivating. These currents are insensitive to the classical K<sup>+</sup> channels blockers 4-aminopyridine, tetraethylammonium, barium and quinidine, but are strongly stimulated by application of arachidonic acid as well as other polyunsaturated fatty acids. hTRAAK can also be activated by a stretch of the membrane.

© 2000 Federation of European Biochemical Societies.

**Key words:** Baseline K<sup>+</sup> channel;  
Two P domain K<sup>+</sup> channel; Mechano-sensitivity

## 1. Introduction

Mammalian K<sup>+</sup> channels with four transmembrane segments and two pore domains in tandem form a novel class of K<sup>+</sup> channels. To date, seven members of this family have been cloned [1–8]. Despite an overall similar structure, the sequence identity between these channels is low (less than 30%). TWIK-1 and TWIK-2 are weak inward rectifying K<sup>+</sup> channels. TASK-1 and TASK-2 are outward rectifying K<sup>+</sup> channels sensitive to variations of extracellular pH in a narrow physiological range. TREK-1, another outward rectifying channel, is activated by membrane stretch, polyunsaturated fatty acids, intracellular acidosis and inhalational anesthetics [9–11]. All these two P domain K<sup>+</sup> channels have a widespread tissue distribution. TRAAK, the second cloned mechano-gated and polyunsaturated fatty acids-activated K<sup>+</sup> channel, is the sole to be expressed exclusively in the mouse central nervous system [5,12,13]. Here we describe the cloning and functional expression of human TRAAK. hTRAAK shares all the functional properties of its mouse counterpart and is also mainly expressed in neuronal tissues [5,12].

## 2. Materials and methods

### 2.1. cDNA cloning

Sequences of two P domain K<sup>+</sup> channels were used to search ho-

mologs in public DNA databases by using the Blast program [14]. This led to the identification of a genomic sequence (GenBank accession number AC005848) which showed significant similarities with mouse TRAAK. Two oligonucleotides were designed from this genomic sequence corresponding to the equivalent sequences flanking the first initiation codon and the stop codon of mTRAAK: sense strand: 5'-AGAATTCGCGCCATGCGCAGCACCACG-3' and antisense strand: 5'-TTTCTCGAGGCCCGCCAGGGATCCTG-3' introducing *EcoRI* and *XhoI* restriction sites, respectively. The entire coding sequence was amplified from human brain cDNA by PCR using these primers and a low-error rate DNA polymerase, then subcloned into the pIRES-CD8 vector to give pIRES-CD8-hTRAAK. Inserts from different independent PCR-ligation experiments were sequenced on both strands and found to be identical.

### 2.2. Chromosomal mapping

The Genebridge 4 RH DNA panel (Research Genetics) was screened by PCR using primers deduced from intron 5 (sense primer: 5'-ACCCAGTGGAGGAGCCCTTC-3') and exon 6 (antisense primer: 5'-GAGGCCCCGCCAGGGATCCTG-3'). PCR conditions were 39 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C. PCR products were separated by electrophoresis on agarose then transferred onto charged nylon membranes. Blots were probed with a <sup>32</sup>P-labeled oligonucleotide 5'-CCAGGCTGCCAGCTGGACRG-3'. The results were analyzed by using the RH-MAPPER program at Whitehead Institute (<http://www.genome.wi.mit.edu>).

### 2.3. RT-PCR experiment

Multiple Tissue cDNA panels (Clontech) were used as template according to the manufacturer's protocol. Sequences of primers were sense primer: 5'-CTCAGTGCTCACCACCATCG-3' (exon 5) and antisense primer: 5'-GAGGCCCCGCCAGGGATCCTG-3' (exon 6). The PCR conditions were 34 cycles of 30 s at 94°C, 30 s at 55°C, and 1 min at 72°C. PCR products were separated, transferred, and probed as described for chromosomal mapping.

### 2.4. Cell culture and transfection

COS-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The pIRES-CD8-hTRAAK plasmid was transfected using the classical DEAE dextran procedure. The positive cells were visualized 48 h after transfection using the anti-CD8 antibody-coated bead method.

### 2.5. Electrophysiology

For whole cell and outside-out experiments, the pipette solution (INT) contained 150 mM KCl, 3 mM MgCl<sub>2</sub>, 5 mM EGTA and 10 mM HEPES, pH 7.2 adjusted with KOH. The bath solution (EXT) contained 150 mM NaCl, 5 mM KCl, 3 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub> and 10 mM HEPES, pH 7.4 adjusted with NaOH. For inside-out experiments the solution in the pipette was EXT and the bath solution was INT. The EXT K<sup>+</sup>-rich solution contained 150 mM KCl instead of 150 mM NaCl. To study the ion selectivity, current–voltage relationships were obtained at different [K<sup>+</sup>]<sub>ext</sub>. For each concentrations, NaCl was substituted in the EXT solution with equimolar KCl.

All products were obtained from Sigma. Fatty acids were dissolved in the ethanol at the concentration of 100 mM, flushed under argon and kept at –20°C for a week. Mechanical stimulation was applied through an open loop pressure generating system and monitored at the level of the patch pipette throughout the experiment by a calibrated pressure sensor.

\*Corresponding author. Fax: (33)-4-93 95 77 04.  
E-mail: [ipmc@ipmc.cnrs.fr](mailto:ipmc@ipmc.cnrs.fr)






Fig. 3. Tissue distribution of TRAANK in human adult tissues as determined by RT-PCR analysis. The amplified products were analyzed by Southern blot. GAPDH was amplified to check the integrity of cDNA.

intestine, prostate and kidney. TRAANK was not detected in the mouse placenta [5]. The reason of this discrepancy is not known. In the mouse, TRAANK is highly expressed only in neuronal tissues, as in humans. In situ hybridization [5] and immunohistology [13] have demonstrated that mouse TRAANK is specifically expressed in neuronal cells. The tissue distribution shown in Fig. 3 suggests that TRAANK could have the same restricted pattern of expression in humans.

### 3.3. Biophysical properties

The electrophysiological experiments were performed in transiently transfected COS cells. hTRAANK current has no apparent voltage activation threshold, is time-independent and non-inactivating (Fig. 4A). The  $I$ - $V$  curve is outward rectifying and noisy at positive potentials (Fig. 4A,B). In a physiological condition (5 mM  $K^+$  ext), hTRAANK current reverses at the predicted value for the  $K^+$  equilibrium ( $-87.1 \pm 1.2$  mV,  $n=6$ ). When the external  $Na^+$  is substituted with  $K^+$  the reversal potential closely follows the value for the  $K^+$  equilibrium (Fig. 4C). The slope of the regression line is  $58.6 \pm 0.6$  mV per 10-fold change in  $[K^+]_{ext}$  ( $n=6$ ) which is in agreement with the Nernst equation for a  $K^+$  selective channel. In a symmetrical condition (155 mM  $K^+$  ext), the  $I$ - $V$  curve is less outward rectifying (Fig. 4A,B) and reverses at  $0.8 \pm 1.1$  mV ( $n=6$ ). The pharmacological properties of hTRAANK were investigated in the whole cell configuration. hTRAANK is insensitive to the classical  $K^+$  channel blockers quinidine (100  $\mu$ M), 4AP (3 mM), TEA (10 mM), barium (1 mM) and glibenclamide (10  $\mu$ M). Some members of the two P domains  $K^+$  channels family (TREK-1 and TASK-1) have been shown to be opened by volatile general anesthetics [11]. We then investigated the effect of chloroform on hTRAANK. Application of chloroform (0.8 mM,  $n=8$ ) has no effect on the channel activity. The single channel properties of hTRAANK are illustrated in Fig. 1D. At the microscopic level, in physiological  $K^+$  condition, the hTRAANK current is outwardly rectifying and is characterized by a flickering behavior.

The mouse TRAANK is stimulated by the poly-unsaturated fatty acids [5,12]. Fig. 5A,B shows that human TRAANK activity is also potentiated by 10  $\mu$ M of arachidonic acid (AA) in the whole cell configuration ( $630 \pm 101\%$  at 0 mV,  $n=19$ ). This activation is completely reversible upon washout (Fig. 5A, inset). In physiological condition, the AA-induced current is outwardly rectifying and reverses at  $-80.6 \pm 0.9$  mV,  $n=7$  (Fig. 5A). When the external  $Na^+$  is substituted with  $K^+$ , the current becomes linear and the reversal potential shifts to  $-0.6 \pm 0.8$  mV,  $n=7$  (Fig. 5B). hTRAANK is also activated by the poly-unsaturated fatty acid docosahexaenoate (10  $\mu$ M,

$n=3$ ) but insensitive to the saturated fatty acids myristate, palmitate, stearate, arachidate (10  $\mu$ M,  $n=6-8$ ). Moreover, AA derivatives with an alcohol or a methyl ester substituted in the carboxylic function are inactive ( $n=5$ ). The AA-stimulation of hTRAANK remains when the patch is excised (Fig. 5C). The AA-induced current observed in the outside-out configuration is outwardly rectifying and reverses at the  $K^+$  reversal potential (Fig. 5C, inset). We have demonstrated that the two P domains  $K^+$  channels activated by the polyunsaturated fatty acids (mTREK-1 and mTRAANK) are mechano-gated  $K^+$  channels. Channel opening is mediated by membrane deformation [10,12]. Fig. 5D illustrates the mechano-sensitivity of hTRAANK. In the inside-out patch configuration, channel activity is almost absent at atmospheric pressure. Application of negative pressure opens the channels in a dose-dependent manner. Taken together, these results demonstrate that human TRAANK shares the same biophysical and pharmacolog-




Fig. 4. Biophysical properties of the human TRAANK. A: Currents elicited by voltage pulses in 20 mV increments from  $-120$  mV to  $100$  mV in a physiological condition (5 mM  $K^+$  ext), left panel or in a symmetrical condition (155 mM  $K^+$  ext), right panel. The holding potential is  $-80$  mV and the zero current is indicated by horizontal arrows. B: current-voltage ( $I$ - $V$ ) curves of the hTRAANK in physiological and symmetrical  $K^+$  conditions. The holding potential is  $-80$  mV and voltage ramps of 800 ms in duration are applied every 10 s from  $-130$  to  $100$  mV. C: Reversal potential of hTRAANK current ( $E_{rev}$ ) as a function of  $[K^+]_{ext}$  ( $n=6$ ). D: Single channel hTRAANK currents recorded in physiological  $K^+$  condition, in the inside-out configuration at  $-50$ ,  $0$  and  $50$  mV.




Fig. 5. hTAAK is an AA-activated and a mechano-gated K<sup>+</sup> channel. A: Whole cell recording of a hTAAK-transfected COS cell illustrating the effect of 10  $\mu$ M AA. *I*-*V* curves were constructed using the same protocol as in Fig. 4B. The bath solution is EXT (5 mM K<sup>+</sup>). The inset shows a typical current recorded at 0 mV during the application of 10  $\mu$ M AA. The zero current is indicated by a horizontal dashed line (a different cell from A). B: *I*-*V* curve performed with the EXT K<sup>+</sup>-rich solution. (same cell as in A). C: Outside-out patch clamp experiment showing the effect of 10  $\mu$ M AA on a hTAAK-transfected COS cell. The patch is maintained at 0 mV. The zero current is indicated by a horizontal dashed line. The inset shows the current-voltage relationship of such an experiment (a different cell from C). D: Graded reversible negative pressure activation of hTAAK in physiological K<sup>+</sup> condition, in the inside-out configuration. The patch is held at 0 mV and the zero current is indicated by a dashed line.

ical properties as its mouse counterpart and has similar properties to K<sup>+</sup> currents previously identified in the central nervous system [17]. Together with hTREK-1, hTAAK constitutes a novel class of AA- and stretch-activated K<sup>+</sup> channels in human.

**Acknowledgements:** We wish to thank V. Lopez for secretarial assistance. This work was supported by the Centre National de la Recherche Scientifique (CNRS) and by the Association Française contre les Myopathies (AFM).

## References

- [1] Kim, D., Fujita, A., Horio, Y. and Kurachi, Y. (1998) *Circ. Res.* 82, 513–518.
- [2] Lesage, F., Guillemare, E., Fink, M., Duprat, F., Lazdunski, M., Romey, G. and Barhanin, J. (1996) *EMBO J.* 15, 1004–1011.
- [3] Fink, M., Duprat, F., Lesage, F., Reyes, R., Romey, G., Heurteaux, C. and Lazdunski, M. (1996) *EMBO J.* 15, 6854–6862.
- [4] Duprat, F., Lesage, F., Fink, M., Reyes, R., Heurteaux, C. and Lazdunski, M. (1997) *EMBO J.* 16, 5464–5471.
- [5] Fink, M., Lesage, F., Duprat, F., Heurteaux, C., Reyes, R., Fosset, M. and Lazdunski, M. (1998) *EMBO J.* 17, 3297–3308.
- [6] Chavez, R.A., Gray, A.T., Zhao, B.B., Kindler, C.H., Mazurek, M.J., Mehta, Y., Forsayeth, J.R. and Yost, C.S. (1999) *J. Biol. Chem.* 274, 7887–7892.
- [7] Reyes, R., Duprat, F., Lesage, F., Fink, M., Salinas, M., Farm-an, N. and Lazdunski, M. (1998) *J. Biol. Chem.* 273, 30863–30869.
- [8] Salinas, M., Reyes, R., Lesage, F., Fosset, M., Heurteaux, C., Romey, G. and Lazdunski, M. (1999) *J. Biol. Chem.* 274, 11751–11760.
- [9] Maingret, F., Patel, A.J., Lesage, F., Lazdunski, M. and Honore, E. (1999) *J. Biol. Chem.* 274, 26691–26696.
- [10] Patel, A.J., Honore, E., Maingret, F., Lesage, F., Fink, M., Duprat, F. and Lazdunski, M. (1998) *EMBO J.* 17, 4283–4290.
- [11] Patel, A.J., Honore, E., Lesage, F., Fink, M., Romey, G. and Lazdunski, M. (1999) *Nat. Neurosci.* 2, 422–426.
- [12] Maingret, F., Fosset, M., Lesage, F., Lazdunski, M. and Honore, E. (1999) *J. Biol. Chem.* 274, 1381–1387.
- [13] Reyes, R., Lauritzen, I., Lesage, F., Ettaiche, M., Fosset, M. and Lazdunski, M. (2000) *Neuroscience* 95, 893–901.
- [14] Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990) *J. Mol. Biol.* 215, 403–410.
- [15] Arrighi, I., Lesage, F., Scimeca, J.C., Carle, G.F. and Barhanin, J. (1998) *FEBS Lett.* 425, 310–316.
- [16] Wang, Z.W., Kunkel, M.T., Wei, A., Butler, A. and Salkoff, L. (1999) *Ann. N.Y. Acad. Sci.* 868, 286–303.
- [17] Kim, D.H., Sladek, C.D., Aguadovelasco, C. and Mathiasen, J.R. (1995) *J. Physiol. (London)* 484, 643–660.